Author Topic: (Abst.) Pathologic findings of chronic PML-IRIS in patient w/prolonged PML survival after Tysabri  (Read 58 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8282
  • MS diagnosed 1980
  • Location: Pacific Northwest
Those who develop PML-IRIS in connection with taking Tysabri are usually stabilized in about 6 months but these researchers suggest that a patient who developed IRIS 3.5 years after developing Tysabri-related PML (and died) indicate that "prolonged low-grade inflammation may persist in some patients."

From PubMed, October 11, 2017:

Quote
J Investig Med High Impact Case Rep. 2017 Sep 27;5(3):2324709617734248.

Pathologic Findings of Chronic PML-IRIS in a Patient with Prolonged PML Survival Following Natalizumab Treatment

Himedan M1, Camelo-Piragua S1, Mills EA1, Gupta A1, Aburashed R2, Mao-Draayer Y1.

Author information

1
University of Michigan, Ann Arbor, MI, USA.
2
Michigan State University, East Lansing, MI, USA.

Immune reconstitution inflammatory syndrome (IRIS) is a common complication during treatment for natalizumab-associated progressive multifocal leukoencephalopathy (PML). Although severe IRIS can result in acute worsening of disability and is associated with poor prognosis, effective immune reconstitution may account for the high survival rate of this cohort of PML patients.

We present pathological evidence of chronic IRIS 3.5 years after diagnosis with natalizumab-associated PML. Our case showed that the IRIS initially developed after plasma exchange therapy and resolved clinically and radiologically following a combination treatment with corticosteroids, maraviroc, and cidofovir.

Autopsy 3.5 years later revealed evidence of grey-white matter junction demyelinating lesions characteristic of PML and perivascular leukocyte infiltrates predominated by CD8+ T-lymphocytes, and polymerase chain reaction analysis demonstrated the presence of JC viral DNA in this tissue, indicative of persistent PML-IRIS. While clinical symptoms of PML-IRIS typically stabilize within 6 months, our case report suggests that prolonged low-grade inflammation may persist in some patients. Better assays are needed to determine the prevalence of prolonged low-grade IRIS among PML survivors.

The abstract can be seen here.
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics